Zurueck zur Suche

Reporte zur Charge nN73FA

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

28Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
TX 5 AZ 4 MI 4 IL 3 WA 2 NV 2 VA 1 OR 1 DE 1 NJ 1 NY 1 OH 1

VAERS 2596160

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

kritisch
Staat
TX
Alter
16,0
Geschlecht
M
Eingang
14.03.2023
Impfdatum
11.03.2023
Beginn
11.03.2023
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Coma scale Fall Muscle spasms Syncope

Symptomtext

PATIENT RECEIVED THE ABOVE FULL SET OF VACCINES. UPON COMPLETION OF VACCINE ADMINISTRATION, PATIENT WAS LEAVING VACCINE ROOM WHEN HE EXPERINCED SOME DEGREE OF BODY SPASMS AND SYNCOPE, HE FELL TO THE FLOOR. PATIENT WAS IMMEDIATELY ASSISTED BY MEDICAL STAFF AND TRANSFERRED TO EXAM ROOM. PATIENT WAS ASSESSED BY SITE AND FOUND TO BE VITALLY STABLE, AAOX4, GCS 15. PATIENT STATED HE FELT FINE AND SPENT THE REST OF THE NIGHT IN OBSERVATION. PATIENT HAD A STABLE NIGHT WITHOUT ANY FURTHER INCIDENTS NOR COMPLICATIONS.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Coma scale
Hospital-Tage
-
Labordaten
FULL HEAD TO TOE ASSESSMENT BY MD ON SITE.
Aktuelle Erkrankungen
NONE
Vorgeschichte
NONE
Andere Medikamente
NONE
Allergien
NKDA
Vorherige Impfungen
-

VAERS 2497773

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

schwer
Staat
TX
Alter
13,0
Geschlecht
F
Eingang
03.11.2022
Impfdatum
01.11.2022
Beginn
01.11.2022
Tage bis Beginn
0,0
Dosis
4
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Syncope

Symptomtext

Pt experienced syncopal event 4 min after immunization received. Slight movement noted of left arm and left leg for 15 seconds while syncopal event lasted. Pt regained consciousness 30 seconds after syncopal event started. Applied cold towel to forehead and cheeks, Pt maintained a pulse during syncopal event.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Syncope
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
None reported by Parent
Vorgeschichte
None reported by Parent at time of Immunization.
Andere Medikamente
None reported by Parent
Allergien
None reported by Parent
Vorherige Impfungen
-

VAERS 2470693

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

schwer
Staat
VA
Alter
7,0
Geschlecht
F
Eingang
06.10.2022
Impfdatum
12.09.2022
Beginn
12.09.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Loss of consciousness Musculoskeletal stiffness Somnolence

Symptomtext

After giving 3rd immunization, client went stiff in father's lap and appeared to lose consciousness. Client moved to exam table and feet elevated. Client immediately responsive but sleepy, able to answer questions but sleepy. Oxygen saturation levels 99-100%. Client given sips of water and fruit snacks and after eating several fruit snacks, client returned to baseline.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Loss of consciousness
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2565643

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

mild
Staat
WA
Alter
12,0
Geschlecht
M
Eingang
23.01.2023
Impfdatum
16.01.2023
Beginn
17.01.2023
Tage bis Beginn
1,0
Dosis
2
Route/Site
SYR / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Dizziness Injection site swelling Peripheral swelling

Symptomtext

Pt with swelling report by parent from shoulder to wrist of right arm, and dizziness. Mom states patient has never had an adverse reaction to any vaccinations previously.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Dizziness
Hospital-Tage
-
Labordaten
Referred to ED for evaluation. Family choose not to complete ED eval and monitored at home. Pt's mom took off work one day to be home with him and monitor. F/U phone call to patient's mom on 1/23/23, mom states patient returned to school and is back to his baseline.
Aktuelle Erkrankungen
NA
Vorgeschichte
NA
Andere Medikamente
Omeprazole, MVI
Allergien
Pollen extract
Vorherige Impfungen
-

VAERS 2510918

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

mild
Staat
OR
Alter
0,2
Geschlecht
M
Eingang
17.11.2022
Impfdatum
17.11.2022
Beginn
17.11.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Rash

Symptomtext

Patient developed a full body rash after waiting the first 15 minutes after injections. Patient mother states that patient developed the rash after the injections were given after about 10 minutes. Patient waited an additional 15 minutes, total of 30mintes, and rash did not worsen. Patient was sent home and advise to keep an eye on the rash.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Rash
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
None
Allergien
None
Vorherige Impfungen
-

VAERS 2490054

MERCK & CO. INC. · HEP B (RECOMBIVAX HB) · Charge N73FA

mild
Staat
AZ
Alter
17,0
Geschlecht
M
Eingang
26.10.2022
Impfdatum
25.10.2022
Beginn
25.10.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Immediate post-injection reaction Rash

Symptomtext

Pt broke out In rash immediately after vaccination administered, he was given 25mg Benadryl on site. Pt was transferred out to Hospital to receive care.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Rash
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
N/A
Vorgeschichte
N/A
Andere Medikamente
N/A
Allergien
Allergies to mayonaise
Vorherige Impfungen
-

VAERS 2698420

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
MI
Alter
0,2
Geschlecht
M
Eingang
19.10.2023
Impfdatum
16.10.2023
Beginn
16.10.2023
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered

Symptomtext

Expired dose of Rotavirus (RotaTeq) given

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 2695032

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
AZ
Alter
17,0
Geschlecht
F
Eingang
12.10.2023
Impfdatum
11.10.2023
Beginn
11.10.2023
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age

Symptomtext

MMRV vaccine administered on a 17 year old patient

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
No
Vorgeschichte
No
Andere Medikamente
Fluticasone propionate 50mcg Folic acid 400 mcg
Allergien
NKDA
Vorherige Impfungen
-

VAERS 2667620

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
MI
Alter
0,2
Geschlecht
M
Eingang
08.08.2023
Impfdatum
14.12.2022
Beginn
14.12.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration Overdose Product administered to patient of inappropriate age

Symptomtext

Overdose; Inappropriate schedule of vaccine; This non-serious case was reported by a other health professional via call center representative and described the occurrence of overdose in a 2-month-old male patient who received HBV (Engerix B adult) (batch number N73FA, expiry date 30-JAN-2023) for prophylaxis. Concomitant products included HEPATITIS B VACCINE (ENGERIX-B PEDIATRIC). On 14-DEC-2022, the patient received the 2nd dose of Engerix B adult (rt. vastus lateralis) 1 ml. On 14-DEC-2022, an unknown time after receiving Engerix B adult, the patient experienced overdose (Verbatim: Overdose) and adult product administered to child (Verbatim: Inappropriate schedule of vaccine). The outcome of the overdose and adult product administered to child were unknown. Additional Information: GSK receipt date: 2-Aug-2023 Medical assistant called to inquired that how to proceed with Hepatitis B series. On 3rd May 2023, the patient's mom stated that the patient received 3 shots that day (3rd May 2023) and health care professional thought one might have been an Engerix pediatric dose but there was no documentation or record and was unknown if an Engerix dose was administered. Did not consent to follow-up. The pediatric patient inadvertently received an adult dose of Engerix-B, which led to overdose and adult product administered to child.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
ENGERIX-B PEDIATRIC
Allergien
-
Vorherige Impfungen
-

VAERS 2664863

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
IL
Alter
-
Geschlecht
M
Eingang
02.08.2023
Impfdatum
26.01.2023
Beginn
26.01.2023
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age Underdose

Symptomtext

patient accidentally received 2 doses of Engerix-B, having received the pediatric formulation they are an adult; patient accidentally received 2 doses of Engerix-B, having received the pediatric formulation they are an adult; patient accidentally received 2 doses of Engerix-B, having received the pediatric formulation they are an adult; patient accidentally received 2 doses of Engerix-B, having received the pediatric formulation they are an adult; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 63-year-old male patient who received HBV (Engerix B pediatric) (batch number N73FA) for prophylaxis. Co-suspect products included HBV (Engerix B pediatric) (batch number AX205) for prophylaxis. On 01-MAR-2023, the patient received the 2nd dose of Engerix B pediatric. On 26-JAN-2023, the patient received the 1st dose of Engerix B pediatric. On 26-JAN-2023, not applicable after receiving Engerix B pediatric and an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: patient accidentally received 2 doses of Engerix-B, having received the pediatric formulation they are an adult) and underdose (Verbatim: patient accidentally received 2 doses of Engerix-B, having received the pediatric formulation they are an adult). On 01-MAR-2023, the patient experienced adult use of a child product (Verbatim: patient accidentally received 2 doses of Engerix-B, having received the pediatric formulation they are an adult) and underdose (Verbatim: patient accidentally received 2 doses of Engerix-B, having received the pediatric formulation they are an adult). The outcome of the adult use of a child product, underdose, adult use of a child product and underdose were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 28-JUL-2023 A pharmacist called in to report that a patient accidentally received 2 doses of Engerix-B, having received the pediatric formulation even though they are an adult and wished to receive information about how to proceed. Partial information was given about the event, patient and vaccine. The Vaccine Administration Facility was the same as Primary Reporter. Consented to follow up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2663435

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
TX
Alter
65,0
Geschlecht
U
Eingang
31.07.2023
Impfdatum
20.07.2023
Beginn
20.07.2023
Tage bis Beginn
0,0
Dosis
3
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age Underdose

Symptomtext

pediatric dose of Enegrix-B (10 mcg) was administered to an adult (65 years); pediatric dose of Enegrix-B (10 mcg) was administered to an adult (65 years); This non-serious case was reported by a pharmacist via call center representative and described the occurrence of underdose in a 65-year-old patient who received HBV (Engerix B 10 mcg) (batch number N73FA, expiry date 31-MAY-2024) for prophylaxis. On 20-JUL-2023, the patient received the 3rd dose of Engerix B 10 mcg. On 20-JUL-2023, an unknown time after receiving Engerix B 10 mcg, the patient experienced underdose (Verbatim: pediatric dose of Enegrix-B (10 mcg) was administered to an adult (65 years)) and adult use of a child product (Verbatim: pediatric dose of Enegrix-B (10 mcg) was administered to an adult (65 years)). The outcome of the underdose and adult use of a child product were unknown. Additional Information: GSK receipt date: 24-Jul-2023 The reporter consented to follow-up. An adult patient received a pediatric dose of Engerix-B (10 mcg), which led to underdose and adult use of a child product.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2648093

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
TX
Alter
-
Geschlecht
F
Eingang
21.06.2023
Impfdatum
09.12.2022
Beginn
09.12.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration Product administered to patient of inappropriate age Underdose

Symptomtext

second dose on 31Jan2023 and third dose 10Mar2023; second dose on 31Jan2023 and pediatric dose of Engerix-B on 09Dec2022; Underdose; Adult use of a child product; This non-serious case was reported by a other health professional via call center representative and described the occurrence of underdose in a 55-year-old female patient who received HBV (Engerix B adult) (batch number AX2D5, expiry date 07-DEC-2024) for prophylaxis. Co-suspect products included HBV (Engerix B adult) (batch number 337TC, expiry date 29-MAR-2024) for prophylaxis and HBV (Engerix B pediatric) (batch number N73FA, expiry date 31-MAY-2024) for prophylaxis. On 10-MAR-2023, the patient received the 3rd dose of Engerix B adult. On 31-JAN-2023, the patient received the 2nd dose of Engerix B adult. On 09-DEC-2022, the patient received the 1st dose of Engerix B pediatric. On 09-DEC-2022, not applicable after receiving Engerix B adult and Engerix B adult and an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: Underdose) and adult use of a child product (Verbatim: Adult use of a child product). On 31-JAN-2023, the patient experienced drug dose administration interval too long (Verbatim: second dose on 31Jan2023 and pediatric dose of Engerix-B on 09Dec2022). On 10-MAR-2023, the patient experienced drug dose administration interval too short (Verbatim: second dose on 31Jan2023 and third dose 10Mar2023). The outcome of the underdose, adult use of a child product, drug dose administration interval too long and drug dose administration interval too short were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 15-JUN-2023 The reporter was medical assistant. The Vaccine Administration Facility was the same as Primary Reporter. The reporter consented to follow up. The reporter reported that it was discovered that an employee that was no longer with the clinic administered a pediatric dose of Engerix-B to a 55 year old patient, which led to underdose and adult use of a child product. The patient received 2nd dose of Engerix-B adult later than the recommended schedule, which led to lengthening of vaccination schedule. The patient received 3rd dose of Engerix-B adult earlier than the recommended schedule , which led to shortening of vaccination schedule.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2625189

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
DE
Alter
27,0
Geschlecht
F
Eingang
03.05.2023
Impfdatum
19.04.2023
Beginn
19.04.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age Underdose

Symptomtext

Adult received Pediatric dose; Adult received Pediatric dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of underdose in a 27-year-old female patient who received HBV (Engerix B 10 mcg) (batch number N73FA, expiry date 31-MAY-2024) for prophylaxis. On 19-APR-2023, the patient received Engerix B 10 mcg 10 mcg/mg. On 19-APR-2023, an unknown time after receiving Engerix B 10 mcg, the patient experienced underdose (Verbatim: Adult received Pediatric dose) and adult use of a child product (Verbatim: Adult received Pediatric dose). The outcome of the underdose and adult use of a child product were unknown. Additional Information: GSK Receipt Date: 21-APR-2023 The vaccine administration facility was the same as primary reporter. The reporter consented to follow up via email. The adult patient received Engerix-B 10 mcg, which led to underdose and adult use of a child product.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2592427

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
NJ
Alter
7,0
Geschlecht
M
Eingang
07.03.2023
Impfdatum
06.03.2023
Beginn
06.03.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Circumstance or information capable of leading to medication error No adverse event Wrong product administered

Symptomtext

No adverse reactions , child had duplicate records in system. 1st record under different name and the second record under another name , same name and DOB in our system. The DR used the name that matches our system to order the shots and did not realize the other record was for the same patient. the child needed only flu shot , but received additional 5 shots . Request sent to system to merge the records.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Circumstance or information capable of leading to medication error
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
none
Vorgeschichte
Hydronephrosis as in infant / Nephrologist referral
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 2583797

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
NY
Alter
6,0
Geschlecht
M
Eingang
17.02.2023
Impfdatum
05.12.2022
Beginn
05.12.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product administered to patient of inappropriate age

Symptomtext

6 YO received adult dose; 6 YO received adult dose; This case was reported by a nurse via call center representative and described the occurrence of accidental overdose in a 6-year-old male patient who received HBV (Engerix B adult) (batch number N73FA, expiry date 31st May 2024) for prophylaxis. On 5th December 2022, the patient received Engerix B adult. On 5th December 2022, unknown after receiving Engerix B adult, the patient experienced accidental overdose and adult product administered to child. On an unknown date, the outcome of the accidental overdose and adult product administered to child were unknown. Additional Information: GSK Receipt date: 07-Feb-2023. Reporter's Comment: An adult dose of Engerix-B was administered to a pediatric patient by accident. The reporter consented to follow-up. Additional Supportive Information: An adult dose of Engerix-B was administered to a pediatric patient by accident which led to accidental overdose and adult product administered to child.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2568333

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
IL
Alter
59,0
Geschlecht
F
Eingang
25.01.2023
Impfdatum
17.10.2022
Beginn
17.11.2022
Tage bis Beginn
31,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Underdose

Symptomtext

Engerix B 10mg birth to 19 years of age dosage form dispensed instead of adult dosing Engerix B 20mg

Weitere VAERSDATA-Felder
Praegender Schweregrund
Underdose
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
unknown
Vorgeschichte
unknown
Andere Medikamente
unnkown
Allergien
none
Vorherige Impfungen
-

VAERS 2568076

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
IL
Alter
59,0
Geschlecht
F
Eingang
25.01.2023
Impfdatum
15.11.2022
Beginn
15.11.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
No adverse event Product administered to patient of inappropriate age

Symptomtext

Patient was given Engerix B 0-19 years of age instead of adult dosing. Patient did not have an adverse reaction.

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
unknown
Allergien
none
Vorherige Impfungen
-

VAERS 2562298

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
MI
Alter
27,0
Geschlecht
M
Eingang
18.01.2023
Impfdatum
16.01.2023
Beginn
16.01.2023
Tage bis Beginn
0,0
Dosis
3
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Underdose

Symptomtext

A pediatric dose of HepB was accidentally administered to client instead of an adult dose. Client was contacted and informed of the incident. Staff also explained that because it was a pediatric dose, it would be considered invalid and he would need to receive an adult dose of HepB to complete the series. Staff scheduled client an appointment on 1/18/23 and an adult dose of HepB was administered. Second, the HPV9 was pulled from the inventory and it should have been taken from the private vaccine inventory. Due to client's age, he does not qualify for program. This dose will be replaced with private pay and private vaccine loss report will be completed by my supervisor.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Underdose
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
None reported.
Vorgeschichte
None reported.
Andere Medikamente
None reported.
Allergien
None reported.
Vorherige Impfungen
-

VAERS 2554702

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
NV
Alter
15,0
Geschlecht
F
Eingang
09.01.2023
Impfdatum
06.01.2023
Beginn
01.01.2023
Tage bis Beginn
-
Dosis
3
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered No adverse event

Symptomtext

Patient had no adverse effect. Submitting report as it was a 3rd dose of Hep A administered

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2548993

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
AZ
Alter
7,0
Geschlecht
F
Eingang
03.01.2023
Impfdatum
03.01.2023
Beginn
03.01.2023
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Wrong product administered

Symptomtext

inadvertently gave patient Dtap instead of Tdap on 01/03/2023 at approximately 11:30am.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Wrong product administered
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 2527752

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
AZ
Alter
17,0
Geschlecht
M
Eingang
09.12.2022
Impfdatum
07.12.2022
Beginn
08.12.2022
Tage bis Beginn
1,0
Dosis
2
Route/Site
- / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
No adverse event Product administered to patient of inappropriate age

Symptomtext

There were no adverse effects after 48 hours of follow-up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
None
Allergien
No Known allergies
Vorherige Impfungen
-

VAERS 2526887

MERCK & CO. INC. · HEP B (RECOMBIVAX HB) · Charge N73FA

gering
Staat
TX
Alter
17,0
Geschlecht
F
Eingang
08.12.2022
Impfdatum
07.12.2022
Beginn
07.12.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
UN / UN
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
No adverse event

Symptomtext

Minor previously received 1st dose in HC on 6/2/22 and second dose of vaccine on 11/7/22. Minor received a third dose on 12/7/2022. No adverse reaction

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
N/A
Vorgeschichte
N/A
Andere Medikamente
N/A
Allergien
N/A
Vorherige Impfungen
-

VAERS 2505740

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
MI
Alter
19,0
Geschlecht
F
Eingang
11.11.2022
Impfdatum
04.11.2022
Beginn
04.11.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Unevaluable event

Symptomtext

n/a

Weitere VAERSDATA-Felder
Praegender Schweregrund
Unevaluable event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2499574

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
OH
Alter
1,2
Geschlecht
M
Eingang
04.11.2022
Impfdatum
02.10.2022
Beginn
-
Tage bis Beginn
-
Dosis
2
Route/Site
IM / LL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered

Symptomtext

Advised mother of the administered dose one of Pediarix and administered 2nd dose of Hep-B instead of just Pediarix. Unauthorized age group: Patient received 10 mcg/0.5ml Hep-B in left leg. Vaccine administered by employee. The director of nursing spoke with the patients mother on 11/4/2022 @ 5:40p. The mother denies the patient has/had any adverse event(s) from the vaccine. The mother states:"he is his normal self. So far so good." Explained to the mother to report any problems, PCP and to take patient to the emergercy room with any adverse affects. Answered all questions and gave mother Directors contact information.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
None
Allergien
None
Vorherige Impfungen
-

VAERS 2492649

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
MD
Alter
11,0
Geschlecht
F
Eingang
28.10.2022
Impfdatum
28.10.2022
Beginn
28.10.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Visual impairment

Symptomtext

Patient tolerated well after the vaccination for 15minutes and left the clinic. Patient went to gym class and ran. Patient complained of changes of vision after the running and came back to health suite. She could see, but unable to see clearly. She said she saw 2 fingers when I showed one finger. She was able to walk and pick up tissue without problem. Her normal vision came back in 15-20minutes, but guardian came to take the student to home.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Visual impairment
Hospital-Tage
-
Labordaten
Eye assessment done. No abnormal finding was noted after she have her normal vision back.
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
None
Vorherige Impfungen
-

VAERS 2486881

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
WI
Alter
13,0
Geschlecht
F
Eingang
24.10.2022
Impfdatum
18.10.2022
Beginn
18.10.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Wrong product administered

Symptomtext

While vaccinating at an offsite clinic at Middle School, Staff administered a Hep B vaccine to the patient instead of the scheduled TDAP.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Wrong product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2477571

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
NV
Alter
17,0
Geschlecht
F
Eingang
13.10.2022
Impfdatum
03.10.2022
Beginn
03.10.2022
Tage bis Beginn
0,0
Dosis
3
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product storage error

Symptomtext

Fridge Temp excursion on multiple dates, IPV administered and was not viable at time of vaccination.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
Myalgia
Vorgeschichte
-
Andere Medikamente
None
Allergien
NKDA
Vorherige Impfungen
-

VAERS 2450882

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge N73FA

gering
Staat
WA
Alter
49,0
Geschlecht
F
Eingang
19.09.2022
Impfdatum
16.09.2022
Beginn
16.09.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Underdose

Symptomtext

Vaccinator administered a child's dose 0.5 mL of Energrix-B using a pre-filled syringe from the childhood vaccine inventory rather than an adult 1.0 mL dose from the vaccine for adults inventory. The child dose is 1/2 of the adult dose. The patient had left the clinic when the error was realized. We are contacting the patient to request that they return for the full dose per guidelines. The two inventories of vaccine were stored in separate refrigerators in clearly labeled bins for clarity prior to the error. Now additional staff training and refrigerator labeling are in place to ensure this error does not happen again.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Underdose
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
No.
Vorgeschichte
-
Andere Medikamente
-
Allergien
Stated yes on consent but with further discussion with nurse the response was determined to be no, no allergies.
Vorherige Impfungen
-